About
First Name:
Last Name:
Title and Organization:
Bio:
Garheng Kong is founder and managing partner of HealthQuest Capital, a healthcare venture capital and growth equity firm. He has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer. Garheng’s investments and board directorships have resulted in the IPOs of Cempra, Alimera, Applied Genetic Technology Corp, Proteon, Histogenics and TransEnterix. He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (United Health) and SARCode (Shire). Garheng has been asked to chair the board of seven companies, and he currently serves on the boards of Alimera Sciences, Castle Biosciences, Cempra, First Aid Shot Therapy, Histogenics, Strongbridge, Trice Medical, Magnolia Medical, Scribe America, Laboratory Corporation of America and Duke University Medical Center Board of Visitors. Garheng’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, and Cure Network Ventures; and he advises IDEO Palo Alto and numerous industry groups. He has served on the Duke Medical Center Institutional Review Board (IRB) and as faculty and a senior scholar at the Duke Fuqua School of Business. Garheng’s early career included stints at GlaxoSmithKline, McKinsey and medical device startup TherOx. He has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Garheng received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. Garheng is a a Fellow of the third class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.
Fellowship Program
Class
My Connections
Total Connections: 8
